4 completed, 2 unknown. 6 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 6 | Completed 4, Unknown 2 |
Follow Postprandial Period: new trials by email Literature Review of Postprandial Period trials Research Report on Postprandial Period
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Food Effect on the Bioavailability of 4-MUST, Tablets, 128 mg 4-MUST, 2 tablets, fasted, 4-MUST, 2 tablets, after meals - Cholecystitis | Phase 1 | Unknown | Valenta Pharm JSC | 24 | 2024-03-19 | 2024-04-02 |
| Human Bioequivalence Test (Fasting & Postprandial) of Iloperidone Tablets Iloperidone 1 MG, Placebo, fasting - Bioequivalence | Phase 1 | Unknown | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 36 | 2017-11-17 | 2018-02-05 |
| Pharmacokinetics Study of Zolpidem Hemitartarate Orodispersible Tablet 3.5 mg Formulation zolpidem hemitartarate tablet 3.5 mg (fasting + post-prandial), zolpidem hemitartarate tablet 3.5 mg (post-prandial + fasting) - Healthy | Phase 1 | Completed | Biolab Sanus Farmaceutica | 28 | 2017-07-05 | 2018-06-11 |
| Single Dose Study of ALZ-801 Prototype Tablets ALZ-801 170 mg Fasting, ALZ-801 205 mg Fasting, ALZ-801 205 mg After Food - Alzheimer Disease | Phase 1 | Completed | Alzheon Inc. | 12 | 2015-09-16 | 2020-10-14 |
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Food-Effect of KQ-791 KQ-791, KQ-791 (after meal), Placebo - Healthy Volunteers, Insulin Resistance | Phase 1 | Completed | Kaneq Bioscience Limited | 19 | 2015-02-01 | 2019-11-26 |
| Study to Evaluate the Pharmacokinetics & Food Effect of MK-0941 in Adults With Type 2 Diabetes (MK-0941-009) 10 mg MK-0941 DFC (fasted), 10 mg MK-0941 OCT (after meal), 10 mg MK-0941 OCT (before meal) - Type 2 Diabetes Mellitus | Phase 1 | Completed | Merck Sharp & Dohme LLC | 18 | 2007-11-01 | 2015-03-23 |
Alzheimer Disease (1) · Cholecystitis (1) · Diabetes Mellitus, Type 2 (1) · Insulin Resistance (1)
Alzheon Inc. (1) · Biolab Sanus Farmaceutica (1) · CSPC ZhongQi Pharmaceutical Technology Co., Ltd. (1) · Kaneq Bioscience Limited (1) · Merck Sharp & Dohme LLC (1) · Valenta Pharm JSC (1)
Brazil (1) · Canada (1) · China (1) · Russia (1)
Ann Church, PhD (1)